Directory of Pharma Companies and News
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofiâ€™s programs in oncology and immunology.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
|2018-10-16||DupixentÂ® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with...|
|2018-10-10||Sanofi Presents 8-Year Data on LemtradaÂ® (Alemtuzumab)|
|2018-10-10||Sanofi presents new data on AubagioÂ® (teriflunomide)|
|2018-10-08||More Than 30 Data Presentations from Sanofi Genzymeâ€™s Multiple Sclerosis Franchise to Be Featured at the 34th ECTRIMS Co...|
|2018-10-08||LibtayoÂ® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation|
|2018-09-28||FDA approves LibtayoÂ® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma|
|2018-09-15||Positive Phase 3 results presented for DupixentÂ® (dupilumab) show significant improvement on multiple measures of diseas...|
|2018-09-03||Cabliviâ„˘ (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)|
|2018-07-18||Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Mu...|
|2018-06-04||New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squam...|